Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Cobbold

Mark Cobbold, Birmingham GB

Patent application numberDescriptionPublished
20110229908METHODS AND PRODUCTS FOR MEASURING FREE IMMUNOGLOBULIN LIGHT CHAIN MOLECULES - The present invention provides improved methods for measuring the ratio of free K immunoglobulin light chain molecules to free λ immunoglobulin light chain molecules in a test sample, using a monoclonal antibody that specifically binds to free K and a monoclonal antibody that specifically binds to free λ. The application also provides specific monoclonal antibodies that can be used in the method of the invention, as well as kits containing said monoclonal antibodies.09-22-2011

Mark Cobbold, Stittsville CA

Patent application numberDescriptionPublished
20110246594METHOD AND APPARATUS FOR ENABLING COMMUTER GROUPS - A commuter groups service (CGS) allows commuters to join commuter groups so that they are able to socialize while commuting. Through the commuter groups, the users may share commuting routes, traffic updates, road conditions, and other information. Group members may arrange car pools, short term riding arrangements, and may anonymously or directly contact each other. The CGS may collect group member position information, e.g. GPS information, to enable the CGS to calculate traffic conditions and to select location specific information for group members. The system may include an on-line service accessible through a computer or wireless networking device. The user may log into the CGS, create or modify a user profile, and join groups of their choosing. Groups may be associated with specific events or with getting to/from work. Commuter groups may be formed for commuters that use private vehicles and/or public transportation.10-06-2011

Stephen Cobbold, Witney GB

Patent application numberDescriptionPublished
20110008330Compositions and methods of tolerizing a primate to an antigen - Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.01-13-2011